Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR5A1 | Q13285 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 3/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 3/20 | 0.35 |
| ▸ | THRB | P10828 | 3/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.33 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18029910 | 0.82 | MEN1 (0.36) | NR5A1CDK1CCNB1FAAHMGLL | |
| SCHEMBL18005390 | 0.82 | MEN1 (0.36) | NR5A1CDK1CCNB1FAAHMGLL | |
| SCHEMBL2235262 | 0.77 | TYR (0.35) | ESR1THRBGPR84 | |
| SCHEMBL2236713 | 0.77 | TYR (0.35) | ESR1THRBGPR84 | |
| SCHEMBL15305976 | 0.77 | TYR (0.35) | ESR1THRBGPR84 | |
| SCHEMBL19127440 | 0.75 | NR5A1 (0.42) | NR5A1ESR1CDK1CCNB1FAAH | |
| SCHEMBL2232923 | 0.75 | TYR (0.33) | ESR1THRBGPR84 | |
| SCHEMBL12352015 | 0.73 | LMNA (0.37) | THRATHRB | |
| SCHEMBL14141549 | 0.73 | NR5A1 (0.46) | NR5A1ESR1LTA4HAKR1C4AKR1C3 | |
| SCHEMBL18005222 | 0.70 | ALDH1A1 (0.44) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3719006-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3719006-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2022-04-06 | — | — | EP | disclosed |
| EP-3719006-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | Arizona Board of Regents on behalf of Arizona State University (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719006-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | Arizona Board of Regents on behalf of Arizona State University (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3259254-B1 | DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3259254-B1 | DEUTERATED AND UNDEUTERATED 2-AMINO-PYRIMIDIN-5-OL DERIVATIVES FOR TREATING MITOCHONDRIAL DISEASES (E.G. OBESITY) | UNIV ARIZONA STATE (US) | 2020-07-01 | — | — | EP | disclosed |
| US-10364227-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-10364227-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-07-30 | — | — | US | disclosed |
| US-20180319751-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-11-08 | — | — | US | disclosed |
| WO-2016133959-A9 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-02-22 | — | — | WO | disclosed |
| WO-2016133959-A9 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-02-22 | — | — | WO | disclosed |
| EP-3259254-A1 | THERAPEUTIC COMPOUNDS | Arizona Board of Regents on behalf of Arizona State University (US) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016133959-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016133959-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319751-A1 | THERAPEUTIC COMPOUNDS | SDHA, CYP11B1, CYP11B2 | NR5A1 369/4885ESR1 3761/4885CDK1 1527/4885 |
| US-10364227-B2 | Therapeutic compounds | SDHA, CYP11B1, CYP11B2 | NR5A1 369/4885ESR1 3761/4885CDK1 1527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.